News
Eli Lilly says weight loss pill leads to 12 percent more weight loss
Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval. Patients taking the pill called orforglipron, an oral GLP-1 receptor, lost almost 12% of their body weight,
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
1don MSN
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
The iPhone maker's shares [rallied for a second day]( ...
Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug ...
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...
Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback